The clinical AI landscape is consolidating rapidly, and Doximity appears to be emerging as a dominant platform. The physician networking company now serves more than 190 health systems—up from 165 just last quarter—and has achieved 34% year-over-year growth in quarterly active workflow prescribers, reaching approximately 900,000 of the nation's 1.8 million prescribers.

The expansion includes 10 of the top 20 U.S. hospitals and represents a shift in how healthcare organizations are approaching AI adoption. Rather than allowing physicians to experiment with disparate AI tools, health systems are consolidating around enterprise-approved platforms that offer integrated workflows, governance structures, and EHR connectivity.

Enterprise Integration Drives Adoption

Major academic medical centers are leading the charge. NewYork-Presbyterian has integrated Doximity's AI tools directly into EHR workflows across 10 hospitals and hundreds of locations, serving clinicians at Columbia University Irving Medical Center and Weill Cornell Medicine. UCSD Health is among the first adopters of Doximity's new patient context feature, which ingests EHR charts, labs, and patient history to provide AI-powered clinical guidance.

This patient context capability represents a workflow improvement, reducing prompt length by 50%—from an average of 24 words to just 12—by eliminating the need for physicians to manually retype chart details. The feature is now available to thousands of doctors across participating health systems.

Doximity's suite spans ambient documentation (Doximity Scribe), clinical decision support (Doximity Ask), telehealth, scheduling, and medication safety verification (DoseCheck). The company has also partnered with Wolters Kluwer Health to embed UpToDate's evidence-based clinical content—authored by 7,600 physicians—directly within its AI tools.

Financial Performance Reflects Market Momentum

The company's Q2 FY2027 financial results (ending September 30) demonstrate the commercial viability of its approach. Revenue reached $174.5 million, up 4% year-over-year and beating guidance of $170.8 million. Adjusted EBITDA hit $89 million with a 51% margin, despite AI spending growing more than sixfold year-over-year.

Doximity raised its full-year revenue outlook to $678-683 million, representing approximately 6% growth at midpoint, with adjusted EBITDA expected between $317-325 million.

Beyond health system subscriptions, the company has created a second revenue stream through AI Search, an advertising product for pharmaceutical companies launched in late April 2026. Already, 16 of the top 20 pharmaceutical companies have purchased the product, with three more in contracting, generating eight-figure bookings. The company is targeting an estimated $14 billion spent annually by pharma on paid search in the U.S.

Addressing the Accuracy Imperative

CEO Jeff Tangney emphasized that "AI accuracy is the number one concern doctors have about AI. AI deals in probabilities. Patient care demands precision." This concern is driving Doximity's strategy of combining probabilistic AI models with deterministic verification tools like DoseCheck and authoritative clinical content partnerships.

The approach appears to be resonating with health systems navigating the transition from what some have characterized as the "Wild West" of AI adoption to governed enterprise deployments with privacy and security controls. With over 300 enterprise clients on telehealth and other products—representing nearly half of all U.S. physicians—Doximity has established relationships that position it as a potential default clinical AI platform.

CFO Matt Sonefeldt noted that workflow active-user growth was "single digits" a year ago versus 34% now, suggesting the market may be reaching an inflection point where comprehensive, enterprise-grade AI platforms are displacing fragmented point solutions.

Sources

  1. Doximity expands clinical AI footprint to more than 190 health systems — Fierce Healthcare